PROTHENA CORP PUBLIC LTD CO (PRTA)
Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy
Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy
📈 **POSITIVE** • Medium confidence analysis (74%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business